In Brief: Guidant
This article was originally published in The Gray Sheet
Executive SummaryGuidant: Initial implants of the firm's Ventak AV automatic implantable cardioverter defibrillator completed in Europe. The Ventak AV incorporates Guidant's Atrial View rhythm discrimination technology, which reads electrical signals taken from the heart's atrium to "discriminate between fast atrial arrhythmias that are not life-threatening and fast ventricular arrhythmias that are," Guidant says...
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.